Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) shares were down 8.6% on Friday . The stock traded as low as $16.81 and last traded at $16.93. 300,058 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 718,964 shares. The stock had previously closed at $18.53.
Analyst Ratings Changes
Several brokerages have recently weighed in on KLRA. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings assumed coverage on Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. TD Cowen started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price on the stock. Finally, Evercore started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.75.
View Our Latest Research Report on Kailera Therapeutics
Kailera Therapeutics Stock Down 8.6%
Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System purchased a new stake in Kailera Therapeutics in the 2nd quarter worth $309,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $24,233,000. Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $64,308,000. Finally, Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics in the second quarter worth about $113,923,000.
Kailera Therapeutics Company Profile
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.
Read More
- Five stocks we like better than Kailera Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Kailera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kailera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
